The seminar and networking forum will give aspiring entrepreneurs and young healthcare businesses an insight into how to start-up, fund and grow innovative new companies. The programme includes practical support and guidance such as how to engage with Technology Strategy Board schemes and how to make the most of R&D tax credits, as well as 'what makes a fundable company'. Confirmed speakers include: - Ian Tomlinson, Senior Vice President, Head of Biopharmaceuticals R&D and Worldwide Business Development, GlaxoSmithKline – an overview on the evolution of Domantis from academia, to small company status and then acquisition
- David Phillips, Partner at SR One Corporate Venturing – what makes a fundable company
- Simon Tate, Chief Scientific Officer of Convergence Pharmaceuticals on his recent experiences in starting up a biotech company – what worked and what didn't
- Jeff Errington, Director of the Institute for Cell and Molecular Biosciences at Newcastle University – BBSRC Innovator of the Year (2009), founder of Prolysis and Demuris, on the challenges of setting up a biotech
- Zahid Latif, Head of Healthcare at Technology Strategy Board – how to engage with Technology Strategy Board programmes
- Colin Haley, Partner at Confluence Tax on R&D tax credits for SMEs
- Martino Picardo, CEO at Stevenage Bioscience Catalyst on open innovation and new ways of working across the interfaces
Further speakers to be confirmed soon.
For further information and to register, please visit www.praxisunico.org.uk/events/other-events.asp. Places are limited so booking early is advisable.
Click here to download the event flyer.
|
